Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722074 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Estonia Pharmaceuticals & Healthcare Report Q1 2008
Business Monitor International, Feb 2008, Pages: 57


  Description  
  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

The Estonia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Estonias pharmaceuticals and healthcare industry.

The Estonian pharmaceutical market is estimated to have reached US$233mn in 2007, rising by 12.5% on the previous year. Key drivers of growth over the next five years will be increased healthcare spending and strong economic growth forecasts, which should push the value of the market to US$331mn by 2012.

Indeed, over the last decade, Estonia has increased its focus on providing public services, with a 10% annual increase in its healthcare spending. Such an investment is urgently needed as poor healthcare has been seen as a weak link in Estonia’s 15-year post-Soviet economic ‘miracle’. However, the country is still struggling with persistent rates of some infectious diseases, including the highest HIV infection rate in the EU by some distance.

In the revised Business Environment Rankings for the 15 major markets of Central & Eastern Europe (CEE), Estonia is found in a respectable fifth place. However, in absolute terms, Estonia will remain a marginal market in the CEE region. The main limiting factor is the small and falling population, which is compounded by the strict reimbursement regime. On a positive note, the country will continue to invest in biotechnology and pharmaceutical research and development (R&D), which is strongly supported by the government.

In the meantime, imports will continue to gain ground in relation to exports, which have tailed off following the recent winding down of manufacturing, as the largest local firm Tallinn Pharmaceutical Plant - part of Latvia’s Grindeks - moved some of its operations abroad. Market expansion is severely limited by strong competition in the supply chain, characterised by a concentrated wholesale market and chain-dominated retail pharmacy landscape.



Customers who bought this item also bought

Estonia Pharmaceuticals and Healthcare Report Q3 2007

Estonia Pharmaceuticals and Healthcare Report Q2 2008

Estonia Pharmaceuticals and Healthcare Report Q4 2008

Estonia Pharmaceuticals and Healthcare Report Q3 2008

Estonia Pharmaceuticals and Healthcare Report Q4 2009

Estonia Pharmaceuticals and Healthcare Report Q2 2009

Estonia Pharmaceuticals and Healthcare Report Q1 2009

Executive Report on Strategies in Estonia

The Pharmaceutical Market: Estonia

Estonia Insurance Report 2008

Estonia Insurance Report 2009

Estonia, Latvia, Lithuania - Banking Market in The Baltics 2009-2011, CEE Banking Brief



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds